AAT-009 is under clinical development by AskAt and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AAT-009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AAT-009 overview
AAT-009 is under development for the treatment of dementia and Alzheimer's disease. AAT-009 acts by targeting the 5-HT4 receptor.
AskAt overview
AskAt is a new kind of life sciences company that is committed to revolutionizing the drug discovery process and delivering truly ground breaking medications to waiting patients around the world. The company is headquartered in Nagoya, Japan.
For a complete picture of AAT-009’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.